Literature DB >> 17709606

Evaluation of prognostic factors of esophageal squamous cell carcinoma (stage II-III) after concurrent chemoradiotherapy using biopsy specimens.

Takayuki Kii1, Hiroya Takiuchi, Shinichiro Kawabe, Masahiro Gotoh, Shunsuke Ohta, Toshimitsu Tanaka, Shin Kuwakado, Hitoshi Nishitani, Ken-ichi Katsu.   

Abstract

BACKGROUND: Recently, attention has been directed to concurrent chemoradiotherapy (CRT) for the treatment of squamous cell carcinoma of the esophagus with regard to efficacy, quality of life and functional preservation, and survival periods comparable to those after standard surgical therapy have been reported in responders to CRT. However, there are some non-responders to CRT, and the prediction of the outcome after CRT is an important subject for future studies. In this study, using biopsy specimens obtained before CRT, we evaluated the relationships between biological markers and the outcome after CRT in order to determine the prognostic factors of CRT.
METHODS: The subjects were 51 patients (42 males and nine females: median age 68 years). who were histologically confirmed to have squamous cell carcinoma of the esophagus at stage II or III (UICC). Concurrent CRT consisting of chemotherapy using 5FU and CDDP and radiation therapy (60 Gy) was performed as the initial treatment, and the relationships of overexpression of EGFR, p53, VEGF, PCNA and CyclinD1 were examined immunohistochemically in biopsy specimens collected before treatment. Overall survival was estimated by multivariate analysis.
RESULTS: The percentages of patients overexpressing p53, VEGF, PCNA, CyclinD1, and EGFR were 33, 31, 37, 31 and 29%, respectively. On multivariate analysis, T stage (P = 0.0393) and PCNA (P = 0.0302) were found to be significant prognostic factors.
CONCLUSIONS: PCNA overexpression appears to be a prognostic factor for squamous cell carcinoma of the esophagus after CRT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17709606     DOI: 10.1093/jjco/hym077

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  6 in total

1.  Characterization of the expression and clinical features of epidermal growth factor receptor and vascular endothelial growth factor receptor-2 in esophageal carcinoma.

Authors:  Madiniyat Niyaz; Jurat Anwer; Hui Liu; Liwei Zhang; Ilyar Shayhedin; Idiris Awut
Journal:  Oncol Lett       Date:  2015-09-25       Impact factor: 2.967

2.  VEGF as a predictor for response to definitive chemoradiotherapy and COX-2 as a prognosticator for survival in esophageal squamous cell carcinoma.

Authors:  Mee Sun Yoon; Taek-Keun Nam; Ji-Shin Lee; Sang-Hee Cho; Ju-Young Song; Sung-Ja Ahn; Ik-Joo Chung; Jae-Uk Jeong; Woong-Ki Chung; Byung-Sik Nah
Journal:  J Korean Med Sci       Date:  2011-03-28       Impact factor: 2.153

Review 3.  Systematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer.

Authors:  Meilan Chen; Jizheng Huang; Zhenli Zhu; Jun Zhang; Ke Li
Journal:  BMC Cancer       Date:  2013-11-11       Impact factor: 4.430

4.  Phosphorylated AKT1 is associated with poor prognosis in esophageal squamous cell carcinoma.

Authors:  Zhengfei Zhu; Weiwei Yu; Xiaolong Fu; Menghong Sun; Qiao Wei; Dali Li; Haiquan Chen; Jiaqing Xiang; Hecheng Li; Yawei Zhang; Weixin Zhao; Kuaile Zhao
Journal:  J Exp Clin Cancer Res       Date:  2015-09-04

5.  Prognostic significance of epidermal growth factor receptor in locally advanced esophageal squamous cell carcinoma for patients receiving chemoradiotherapy.

Authors:  Zhenhua Gao; Xue Meng; Dianbin Mu; Xindong Sun; Jinming Yu
Journal:  Oncol Lett       Date:  2014-02-13       Impact factor: 2.967

6.  Expression of epidermal growth factor receptor is an independent prognostic factor for esophageal squamous cell carcinoma.

Authors:  Qifeng Wang; Hongxia Zhu; Zefen Xiao; Wencheng Zhang; Xiao Liu; Xun Zhang; Jie He; Kelin Sun; Lvhua Wang; Ningzhi Xu
Journal:  World J Surg Oncol       Date:  2013-10-16       Impact factor: 2.754

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.